Long-Acting Injectable HIV Treatment Still Appears Safe and Effective—and Largely Accessible Despite COVID-19 Disruptions
Research newly presented at the IDWeek 2020 conference yields further promising data on injectable cabotegravir/rilpivirine, as well as encouraging info regarding COVID-19 disruptions in treatment delivery.
July 23, 2020: Depression and HIV risk mitigation among MSM; a consistent HIV provider is good for CD4 and viral load; spirituality and HIV prevention; HCV treatment access and reinfection risk.
Hostilities against migrants and indigenous people are also threats to their health.
Two recent coronavirus studies are only the beginning of our understanding of how different antiviral meds interact with the virus.
Some Research on Pregnant and Postpartum Women with HIV Is Presented at CROI, But More Trials Are Needed
Pregnant people who are living with or vulnerable to HIV need to be included in clinical trials in order to close our knowledge gaps.
Addressing Coronavirus in African Countries With High HIV Rates: An Interview With UNAIDS Head Winnie Byanyima
Byanyima discusses COVID-19, HIV, and the power of the community response.
Researchers are happy but cautious, because this isn’t a strategy for most people with HIV.
Nov. 20, 2019: Adherence required to maintain suppression; the accuracy of Framingham scores in assessing cardiovascular risk; long-term success rates for kidney transplants; integration of hypertension services with HIV care.
When Providers Don't Use Gender-Affirming Language, It Negatively Impacts HIV-Positive Transgender Women's Health
A new study shows that helping clinicians use gender-affirming language is important for transgender women in care. But we need more research on how HIV medications and feminizing hormones interact.
The new public-private partnership will put $200 million toward finding eventual cures for two of the world's most pervasive diseases.